First-line therapy with donor-derived HCMV-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation.
Human cytomegalovirus (HCMV) infection, especially persistent HCMV infection, is an important cause of morbidity and mortality after allogenic stem cell transplantation (allo-SCT). Antiviral agents remain the first-line therapy but are limited by side-effects and acquired resistance. We evaluated the safety and efficacy of donor-derived HCMV-specific cytotoxic T cells (CTL) as a first-line therapy for HCMV infection after allo-SCT and investigated the underlying mechanisms. i) In humanized HCMV-infected mice, first-line therapy with CTL effectively combated systemic HCMV infection by promoting the restoration of graft-derived endogenous HCMV-specific immunity in vivo. ii) In a clinical trial, compared to the pair-matched high-risk control cohort, first-line therapy with CTL significantly reduced the rate of persistent (2.9% vs. 20.0%, P=0.018) and late (5.7% vs. 20.0%, P=0.01) HCMV infection and cumulative incidence of persistent HCMV infection (HR=0.13, 95%CI=0.10-0.82, P=0.02), lowered one-year treatment-related mortality (HR=0.15, 95%CI=0.11-0.90, P=0.03) and improved one-year overall survival (HR=6.35, 95%CI=1.05-9.00, P=0.04). Moreover, first-line therapy with CTL promoted the quantitative and functional recovery of CTL in patients, which was associated with HCMV clearance. We provide robust support for the benefits of CTL combined with antiviral drugs as a first-line therapy for treating HCMV infection and suggest that adoptively infused CTL may stimulate the recovery of endogenous HCMV-specific immunity.This trial is registered at www.clinicaltrials.gov as #NCT02985775.